Pilot, prospective, multicentric, open study: use of a new Prismaflex filter (coated with heparin) without any addition of heparin in the extracorporeal circuit. Study with direct individual benefit.
- Conditions
- Continuous Renal Replacement Therapy (CRRT)Urological and Genital Diseases
- Registration Number
- ISRCTN02674550
- Lead Sponsor
- Gambro Industries (France)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 30
1. Patients requiring Continuous Renal Replacement Therapy (CRRT)
2. Patients aged 18 and over
3. Patients weighing 30-120 kg
4. Patients having signed a written consent (informed consent) to participate in the study or written consent from a relative or, failing which, a person of trust in case the patient is unconscious
1. History of heparin antibodies or heparin-induced thrombocytopenia
2. Known hypersensitivity to any dialysis membrane
3. Pregnancy
4. Current enrolment in another trial which could impact the successful completion of this study
5. Patients under guardianship
6. Patients anticipated to require transportation outside the unit for diagnostic or therapeutic procedures in the coming first week
7. Unconscious patients for whom no relative or person of trust can give consent for treatment. In the absence of any relative or person of trust, the patient in question cannot be included in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method